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Abstract
Aim:  Gliomas represent the most frequent neoplasm of the central nervous system.
Unfortunately, surgical cure of it is practically impossible and their clinical course is primarily
determined by the biological behaviors of the tumor cells. The aim of this study was to investigate
the correlation of the stem cell markers Nestin and CD133 expression with the grading of gliomas,
and to evaluate their prognostic value.
Methods: The tissue samples consisted of 56 low- (WHO grade II), 69 high- (WHO grade III, IV)
grade gliomas, and 10 normal brain tissues. The expression levels of Nestin and CD133 proteins
were detected using SABC immunohistochemical analysis. Then, the correlation of the two
markers' expression with gliomas' grading of patients and their prognostic value were determined.
Results:  Immunohistochemical analysis with anti-Nestin and anti-CD133 antibodies revealed
dense and spotty staining in the tumor cells and their expression levels became significantly higher
as the glioma grade advanced (p < 0.05). There was a positive correlation between the two
markers' expression in different gliomas tissues (rs = 0.89). The low expression of the two markers
significantly correlated with long survival of the glioma patients (p < 0.05). The survival rate of the
patients with Nestin+/CD133+ expression was the lowest (p < 0.01), and the multivariate analysis
confirmed that conjoined expression of Nestin+/CD133+ and Nestin-/CD133- were independent
prognostic indicators of gliomas (both p < 0.01, Cox proportional hazard regression model).
Conclusion: These results collectively suggest that Nestin and CD133 expression may be an
important feature of human gliomas. A combined detection of Nestin/CD133 co-expression may
benefit us in the prediction of aggressive nature of this tumor.
Background
Gliomas, the most frequent primary tumors in the human
central nervous system (CNS), are classified into low- and
high-grade glioma according to their morphological fea-
tures [1]. Cells of low-grade (WHO grade I and II) gliomas
are well differentiated with clear histological similarity to
astrocyte or oligodendrocyte lineage. High-grade (WHO
grade III and IV) gliomas are more anaplastic, with fea-
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tures resembling immature astrocytes, oligodendrocytes
or a mixture of both types [2]. A considerable number of
advances on therapeutics of malignant gliomas have been
got in the last decade [3,4]. But unfortunately, surgical
cure, as the basic treatment of malignant gliomas, is prac-
tically impossible to resect effectively because of their
infiltrating nature and high recurrence, as this result, glio-
mas portend a poor prognosis [5,6]. To address this prob-
lem, many investigations have been performed and recent
discoveries have shed light on the genetic events which
lead to human gliomas.
Currently, a growing body of evidence suggests that glio-
mas may be generated from tumor stem cells (TSC) shar-
ing many properties with those of neural stem cells (NSC)
[7,8]. Nestin is an intermediate filament (IF) protein
expressed in proliferating cells during the developmental
stages in a variety of embryonic and fetal tissues [9]. It
may be involved in the organization of the cytoskeleton,
cell signaling, organogenesis, cell metabolism, and repre-
sent the proliferation, migration and multi-differentiated
characteristics of multi-lineage progenitor cells [10].
CD133 (also named as Prominin) is a cell surface marker
expressed on normal human NSC and acutely dissociated
brain tumor cells [11]. Five alternative promoters, three of
which are partially regulated by methylation, drive the
transcription of several mRNA isoforms of CD133. Its
localization is in membrane protrusions, which suggests
an involvement in the dynamic organization of mem-
brane protrusions and therefore in the mechanisms influ-
encing cell polarity, migration and interaction of stem
cells with neighbouring cells and/or extracellular matrix
[12].
It has been reported that TSC expressing the markers Nes-
tin and CD133 in a variety of brain tumors [13]. Analyses
on their expression may be useful in predicting behavior
of tumors in order to identify which tumors are most ame-
nable to therapy. Therefore, the purpose of this study is to
determine the correlation of Nestin and CD133 expres-
sion with the grading of gliomas and their predictive effi-
ciency in clinical outcome of patients.
Materials and methods
Patients and Tissue Samples
Our study was approved by the Ethics Committee of
Xiangya Hospital of Central South University, Changsha,
Hunan, P.R.China. We searched the surgical pathology
database of neurosurgery department of Xiangya Hospital
of Central South University, Changsha, Hunan, P.R.China
for cases from July 11th 1998 to July 7th 2001, and identi-
fied 125 consecutive, surgically resected gliomas. None of
the patients had undergone chemotherapy or radiother-
apy before surgery. There were 85 males and 40 females
(2.125:1), with a mean age of 48.13 years (range form 8
to 75 years). The World Health Organization (WHO)
defines four grades of gliomas with increasing histologic
abnormality [11]. Tumors in grades II to IV are diffuse and
invade normal brain. Grade II tumors are also called "low-
grade gliomas," grade III tumors are called anaplastic, and
grade IV tumors are known as glioblastoma multiforme
(GBM). According to this standard, there were 56 low-
(WHO grade II), 69 high- (WHO grade III, IV) grade glio-
mas. 10 normal brain tissues were used as control samples
for the immunohistochemical analysis.
All patients were given a follow-up ranging from one year
to seven years. The survival periods of the patients with
gliomas were calculated and the date of the initial surgery
was set as zero. All the patients died of other diseases but




The expression levels of Nestin and CD133 in glioma tis-
sues were analyzed by immunohistochemical staining.
Tissues were fixed in 10% buffered formalin and embed-
ded in paraffin. Commercially available monoclonal anti-
bodies to Nestin and CD133 (Santa Cruz™, USA and
Novocostra) were used. Immunohistochemical staining
was carried out using the avidin-biotin method and a
commercially available kit (Vectastain Elite ABC kit, Vec-
tor Laboratories, Burlingame, CA). One paraffin-embed-
ded block of glioma tissue was selected from each case
and cut into 4 m sections. Deparaffinized sections were
treated with methanol containing 3% hydrogen peroxide
for 10 min before conducting antigen retrieval using a
microwave oven at 95°C for 5 min and cooling at 25°C
for 2 hours. After washing with PBS, blocking serum was
applied for 10 min. The sections were incubated with an
anti-Nestin monoclonal antibody (1:500) and anti-
CD133 monoclonal antibody (1:100) overnight at 4°C.
Negative control sections were incubated with PBS instead
of the primary antibody. After washing in PBS, a biotin-
marked secondary antibody was applied for 10 min fol-
lowed by a peroxidase-marked streptavidin for an addi-
tional 10 min. The reaction was visualized by using 3, 3'-
diaminobenzidine tetrahydrochloride. The nuclei were
counterstained with hematoxylin. Positive and negative
immunohistochemistry controls were routinely used.
Reproducibility of staining was confirmed by reimmunos-
taining via the same method in multiple, randomly
selected specimens.
Immunohistochemical staining for Nestin and CD133
was scored for the tumor cells. The number of positive-
staining cells showing immunoreactivity on the cell mem-
branes and cytoplasm in ten representative microscopic
fields was counted and the percentage of positive cells wasJournal of Experimental & Clinical Cancer Research 2008, 27:85 http://www.jeccr.com/content/27/1/85
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calculated. The score of Nestin and CD133 immunoreac-
tivitiy in tissue sections was evaluated as negative (0)
when no positive cells were observed within the tumor,
weak (1+) when < 30% of the tumor cells were positive,
moderate (2+) when 30%~60% of the tumor cells were
positive, and strong (3+) when > 60% of tumor cells were
positive [14,15].
Statistical Analysis
The software of SPSS version12.0 for Windows (SPSS Inc,
IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was used
for statistical analysis. Continuous variables were
expressed as   ± s. Statistical analysis were performed
with Fisher's exact test for any 2×2 tables, Pearson 2 test
for non- 2×2 tables, chi-square trend test for ordinal
datum, Kaplan-Meier and Cox Regression analysis for the
question of survival analysis. The Spearman correlation
was calculated between the expression levels of Nestin
and CD133 in glioma tissues. A difference between means
was considered significant if the p  value was less than
0.05.
Results
Expression of Nestin and CD133 in Human Glioma tissue
The expression and location of Nestin and CD133 in the
125 patients of primary gliomas were examined using
immunostaining analysis. The positive expression rates of
Nestin (103/125, 82.4%) and CD133 (98/125, 78.4%) in
patients with gliomas were higher than those in normal
brain tissues (both 1/10, 10%) significantly (p < 0.001,
Table 1). The two markers expression occurred mainly on
the cell membrane and in the cytoplasm, which is similar
to the results from previous studies [16]. Representative
pictures of immunohistochemistry staining of Nestin and
CD133 are shown in Figure 1.
Correlation of Nestin and CD133 expression with the 
clinical grading of human gliomas
The expression levels of Nestin and CD133 in human gli-
omas tissues with different clinical grading were shown in
Table 2. To evaluate whether a correlation between the
expression of Nestin, CD133 and the pathological grades
of gliomas could be observed a bi-variate correlation anal-
ysis (Pearson correlation coefficients) was done. Statisti-
cally significant correlations between the percentages of
immunostained cells and pathological grades of gliomas
were found for Nestin (cp = 0.592, p < 0.01) and CD133
(cp = 0.563, p  = 0.01), which means that with higher
malignant grades of gliomas, higher protein expression
could be found. Furthermore, the Spearman correlations
(rs) were 0.89 (p = 0.02) indicating that the expression
level of Nestin was positively correlated with that of
CD133 significantly.
Prognostic implications of Nestin and CD133 expression in 
human gliomas
The association of Nestin and CD133 expression with the
5-year survival rate of patients with gliomas was analyzed
using Kaplan-Meier analysis. The patients with positive
Nestin and CD133 were both categorized into three
groups: 0, 1+~2+ and 3+. The Chi-square value by Mantel-
Cox indicated a significant difference among different
groups with regard to the expression status of Nestin and
CD133 (p < 0.01) (Table 3, Figure 2A and 2B). The results
by pairwise comparisons showed that there is a significant
difference in survival rates between patients with Nestin
and CD133 strong positive expression and any of the
other two groups (p < 0.01).
Furthermore, according to the conjoined expression of
Nestin/CD133, the patients were categorized into four
groups: Nestin-/CD133-, Nestin-/CD133+, Nestin+/
CD133-, and Nestin+/CD133+. Among the four groups
Nestin+/CD133+ patients had the poorest prognosis.
Using Cox regression analysis of the 125 patients, con-
joined expression of Nestin+/CD133+ and Nestin-/
CD133-, clinical grading seemed to be independent prog-
nostic indicators. (p < 0.01, p < 0.01 and p = 0.02, respec-
tively, Table 4).
Discussion
To our knowledge, malignant gliomas are highly recurrent
tumors even after surgery, chemotherapy, radiation and
immunotherapy. Ionizing radiation represents the most
effective therapy for gliomas but radiotherapy remains
only palliative because of radioresistance. In the last dec-
ades, the treatment strategies for gliomas have not
changed appreciably because of the limited understand-
ing of the biology of the disease. Several recent reports
suggest that normal and TSCs share the expression of sev-
eral markers, the ability for self-renewal and differentia-
tion, and signalling pathways involved in the regulation
of cellular survival, proliferation [17,18]. It also has been
demonstrated that TSCs exist in high-grade brain tumors
and could be isolated from them. Nevertheless, little is
known about the expression of these markers in solid
brain tumors, especially in relation with the malignant
X
Table 1: Expression of Nestin and CD133 in human gliomas and 
normal brain tissues
Groups Cases (n) 0 (n, %) 1+~2+ (%) 3+ (%) P
Nestin
Gliomas 125 22 (17.6) 68 (54.4) 35 (28.0) < 0.001
Normal 10 9 (90.0) 1(10%) 0 (0)
CD133
Gliomas 125 27 (21.6) 64 (51.2) 34 (27.2) < 0.001
Normal 10 9 (90.0) 1(10%) 0 (0)Journal of Experimental & Clinical Cancer Research 2008, 27:85 http://www.jeccr.com/content/27/1/85
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grades of these tumors. To address this problem, we inves-
tigate, in this study, the expression of two TSC markers –
Nestin and CD133, which are the most accredited markers
for the identification of NSCs and have been used to fun-
damentally reveal the biological properties of TSCs, on
protein level. In our small series of cases, Nestin and
CD133 expression was associated with a poor prognosis
and correlated better with clinical course than the histo-
logical grading. While the prognostic significance of the
histological diagnosis strongly depends on the experience
of the respective neuropathologist, analysis of both avail-
able data sets revealed that Nestin and CD133 expression
was superior in predicting the patient's survival.
Nestin belongs to class VI of IFs, produced in stem cells in
the mammalian CNS during development. It is a marker
of proliferating and migrating cells [19]. IFs as the
cytoskeleton constituents are involved in the control of
cell morphology, adhesion and proliferation. When dif-
ferentiation starts, cells that exit the cell cycle down-regu-
late Nestin and subsequently up-regulate alternative IFs
such as neurofilaments in committed neurons, and GFAP
in glial precursors [20]. Down-regulated Nestin may be re-
expressed in the adult organism under certain pathologi-
cal conditions such as brain injury, ischemia, inflamma-
tion and neoplastic transformation [21]. Nestin has been
detected in brain tumors such as pilocytic astrocytomas
Immunohistochemical analysis for anti-human Nestin and anti-human CD133 antibodies Figure 1
Immunohistochemical analysis for anti-human Nestin and anti-human CD133 antibodies. Paraffin-embedded sec-
tions of representative gliomas and normal brain tissues were stained with the antibodies against human Nestin and CD133. 
The photographs of A and C are normal brain tissues which showed negative or weak staining for Nestin and CD133, respec-
tively. In contrast, the glioblastomas that have high expression levels of Nestin and CD133 with dense and spotty staining were 
shown in B and D, respectively.Journal of Experimental & Clinical Cancer Research 2008, 27:85 http://www.jeccr.com/content/27/1/85
Page 5 of 7
(page number not for citation purposes)
and malignant gliomas including GBM [22-25]. IF is
linked to enhanced motility and invasion in a number of
different cancer subtypes. The expression of Nestin in dif-
ferent astrocytoma cell lines has been related to a migra-
tory cell phenotype with increased motility and
invasiveness of different astrocytoma cell lines [23]. More-
over, Dahlstrand, et al. showed high Nestin expression in
high malignant tumors such as GBM when compared to
less anaplastic glial tumours, which assigns to Nestin a
role as new potential prognostic marker for glioblastomas
[26]. In addition, Nestin has been also identified in the
cell nucleus of tumor cell lines obtained from glioblast-
oma patients [27]. In our work, in agreement with litera-
ture data, Nestin was expressed more frequently in higher
malignant grade gliomas by tumor cells, being predictive
of a significantly lower 5-year survival rate.
CD133/prominin is originally found on neuroepithelial
stem cells in mice. It has been isolated from hematopoi-
etic stem cells by an antibody recognizing AC133 [28]. In
general, CD133 is present in different types of stem cells
and several cancers, and is down-regulated in differenti-
ated cells [29]. CD133 localization in membrane protru-
sions suggests an involvement in the dynamic
organization of membrane protrusions and therefore in
the mechanisms influencing cell polarity, migration and
interaction of stem cells with neighbour cells and/or extra-
cellular matrix, but experimental data are currently lack-
ing [30]. In addition, it is not known whether CD133 has
a role in self-renewal and differentiation of stem cells,
which has important implication in cancerogenesis. Our
study investigated CD133 expression, yielding results sim-
ilar to those reported by Dagmar [11] for CD133 (namely,
a predictive value for a worse outcome in high-grade oli-
godendroglial tumor patients displaying positivity for
CD133 expression).
In conclusion, Nestin and CD133 expression may be a
potential indicator of the biological aggressiveness of gli-
Table 2: Nestin and CD133 expression in human gliomas tissues with different clinical grading
Clinical Grading NO. Nestin (n, %) CD133 (n, %)
0 1+~2+ 3 0 1+~2+ 3
Low-grade tumors 56 16 (28.6) 32 (57.1) 8(14.3) 20 (37.1) 27 (48.2) 9(16.1)
Astrocytoma 18 7 (38.8) 11 (61.1) 0 (0) 9 (50.0) 9 (50.0) 0 (0)
Ependymoma 15 6 (40.0) 8 (53.3) 1 (6.7) 7 (46.7) 7 (46.7) 1 (6.7)
Oligodendroglioma 11 2 (18.2) 8 (72.7) 1 (9.1) 3 (27.3) 7 (63.6) 1 (9.1)
Oligodendroastrocytoma 4 1 (25.0) 1 (25.0) 2 (50.0) 1 (25.0) 1 (25.0) 2 (50.0)
Pilocytic astrocytoma 8 0 (0) 4 (50.0) 4 (50.0) 0 (0) 3 (37.5) 5 (62.5)
High-grade tumors 69 6(8.7) 36 (52.2) 27 (39.1) 7(10.1) 37 (53.6) 25 (36.2)
GBM 48 4 (8.3) 28 (58.3) 16 (33.3) 5 (10.4) 29 (60.4) 14 (29.2)
Anaplastic astrocytoma 11 2 (18.2) 6 (54.5) 3 (27.3) 2 (18.2) 7 (63.6) 2 (18.2)
Malignant oligodendroglioma 6 0 (0) 1 (16.7) 5 (83.3) 0 (0) 1 (16.7) 5 (83.3)
Malignant ependymoma 4 0 (0) 1 (25.0) 3 (75.0) 0 (0) 0 (0) 4 (100.0)
Table 3: Prognostic value of Nestin and CD133 expression by 
Kaplan-Meier analysis
5-year survival rate
TYPE Total N n Percent (%) p
Nestin
0 22 19 86.4 < 0.01
1+~2+ 68 36 52.9
3+ 35 7 20.0
CD133
0 27 22 81.5 < 0.01
1+~2+ 64 31 48.4
3+ 34 7 20.6
Kaplan-Meier survival curves for Nestin (A) and CD133 (B)  expression in gliomas tissues Figure 2
Kaplan-Meier survival curves for Nestin (A) and 
CD133 (B) expression in gliomas tissues. 'a', catego-
rized by negative Nestin or CD133 expression; 'b', catego-
rized by weak~moderate positive Nestin or CD133 
expression; 'c', categorized by strong positive Nestin or 
CD133 expression. Survival was significantly poor for 
patients with strong positive Nestin or CD133 expression 
than those with negative expression (both p < 0.01).Journal of Experimental & Clinical Cancer Research 2008, 27:85 http://www.jeccr.com/content/27/1/85
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omas. With its disease specificity and response to treat-
ment demonstrated in further analysis, Nestin and CD133
can be considered as markers of tumor burden and recur-
rence in human gliomas.
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